Combined pituitary hormone deficiencies, genetic form
MONDO:0013099Congenital hypopituitarism is characterized by multiple pituitary hormone deficiency, including somatotroph, thyrotroph, lactotroph, corticotroph or gonadotroph deficiencies, due to mutations of pituitary transcription factors involved in pituitary ontogenesis. Congenital hypopituitarism is rare compared with the high incidence of hypopituitarism induced by pituitary adenomas, transsphenoidal surgery or radiotherapy.
Also known as: familial congenital hypopituitarism, genetic hypopituitarism, multiple pituitary hormone deficiencies, genetic forms, pituitary hormone deficiency, combined, combined pituitary hormone deficiencies, genetic forms, familial hypopituitarism
43 clinical trials for this condition and its sub-types, 1 tagged with Combined pituitary hormone deficiencies, genetic form itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Combined pituitary hormone deficiencies, genetic form
-
7 sub-types
- Isolated growth hormone deficiency type IA 0 trials
- Isolated growth hormone deficiency type IB 0 trials
- Isolated growth hormone deficiency type II 0 trials
- Isolated growth hormone deficiency type III 0 trials Sub-types →
- Isolated growth hormone deficiency, type 4 0 trials
- Isolated growth hormone deficiency, type 5 0 trials
- Short stature due to growth hormone qualitative anomaly 0 trials
-
Panhypopituitarism 2 trials
2 sub-types
- Panhypopituitarism, X-linked 0 trials
- Pituitary hormone deficiency, combined, 2 0 trials
-
Septooptic dysplasia 1 trial
2 sub-types
- Congenital absence of septum pellucidum 0 trials
- Pagon stephan syndrome 0 trials
Most studied deeper sub-types
-
New growth hormone drug sogroya® tracked in kids for up to 3 years
Disease control By invitation onlyThis study follows 200 children in Japan with growth hormone deficiency who are taking Sogroya® (somapacitan) as part of their normal care. Researchers will monitor side effects and growth over 1 to 3 years to see how safe and effective the drug is in real-world use. Participants…
Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New growth hormone pen under safety watch in korean kids
Disease control OngoingThis study tracks the safety and effectiveness of Ngenla, a growth hormone injection, in over 500 children aged 3 and older with growth hormone deficiency in Korea. Researchers will monitor side effects and growth changes over 6 years during routine medical care. The treatment he…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
10-Year registry to track safety of weekly growth hormone in kids
Knowledge-focused By invitation onlyThis 10-year observational study will follow 500 children with growth hormone deficiency who are receiving the once-weekly injection somapacitan as part of their routine care. Researchers will track side effects, medication errors, and new cases of cancer or type 2 diabetes. The …
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Pituitary patients followed for years to uncover key outcomes
Knowledge-focused OngoingThis study follows 1500 patients with pituitary gland disorders to see how they fare over time, whether treated with medication, surgery, or just monitoring. Researchers will track tumor regrowth after surgery to find clues that predict recurrence. The goal is to learn, not to te…
Sponsor: University of Alberta • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Does sticking to growth hormone treatment help kids grow taller? study aims to find out.
Knowledge-focused By invitation onlyThis study looks at children and teenagers with growth hormone deficiency or who were born small for their age. It tracks how closely they follow their prescribed Norditropin® treatment and whether that affects their final height. The study is observational, meaning no new treatm…
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC